1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Erectile Dysfunction-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017


DelveInsight’s Report, “Erectile Dysfunction-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Erectile Dysfunction Report is to understand the market and pipeline status of the drugs around the Erectile Dysfunction to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsight’s Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Erectile Dysfunction. While the leading brands, companies and chemicals are considered thoroughly, DelveInsight’s report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India.

Please note:This report requires certain updates. We have all the information available but require 48-72 Hours to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE:
- A snapshot of the global Market and Phase III therapeutics scenario for Erectile Dysfunction.
- A review of the marketed products under prescription for Erectile Dysfunction, regulatory information and marketing status.
- Coverage of global patent coverage and detailed commentaries on the US patent challenges.
- Graphical representation of investigational products for patent expiry and market exclusivities across the globe.
- Product profiles for marketed products for Erectile Dysfunction with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.
- Coverage of API Manufacturers for Erectile Dysfunction drugs in the United States, Europe and Asian Regions with location details.
- Coverage of Regulatory filings in theUS, Europe, and Asia specifically India and China for Erectile Dysfunction drugs.
- Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Erectile Dysfunction drugs.
- Coverage of Erectile Dysfunction Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.
- Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.
- Key discontinued Marketed products.
- Global Sales Figure to 2018.

Reasons to buy:
- Evaluate the marketing status and exclusivity details of Erectile Dysfunction key products to exploit opportunities for generic drug development opportunities.
- Identify and understand important and diverse types of therapeutics under Phase III development for Erectile Dysfunction.
- Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Erectile Dysfunction.
- API intelligence over marketed drugs forErectile Dysfunctionand gaining primary intelligence over active ingredients manufacturers across the globe.
- API intelligence over leading Phase III Pipeline drugs.
- Develop and designstrategies by identifying the API manufacturers for Phase III Pipeline products to enhance and expand business potential and scope.
- Understanding the scope of the Phase III Drugs with nil regulatory filings.
- Understanding the chemical route of synthesis of approved drugs for Erectile Dysfunction.
- Uncovering opportunities in the rapidly growing US market.

Table Of Contents

Erectile Dysfunction-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
Illustrative
1. Indication Overview
2. Market Drugs Landscape
2.1 Marketed Drugs
2.2 Marketed Details of Drugs by Application Type
2.3 Marketed Details of Drugs (NDA) by Marketing Status
2.4 Marketed Details of Drugs by Patent Expiration Timeline
3. Global API Manufacturers Assessment
3.1 API Manufacturers by United States Drug Master File (US DMF) Status
3.2 API Manufacturers by US DMF Status (Drug Specific)
3.3 API Manufacturers in Europe by Country
3.4 API Manufacturers in India by State
3.5 API Manufacturers in China by Province
3.6 Marketed Details of Approved Drugs by Geography
4. Phase III Drugs Landscape
4.1 Active Pharmaceutical Ingredient (API) Manufacturers Assessment for Phase III Pipeline Drugs
4.2 API Manufacturers by US DMF Status (Drug Specific)
5. Drugs Market Data and Forecasted Sales Figure-2018
6. Marketed Drugs for Erectile Dysfunction
6.1 Drug Name
6.1.1 Drug Description
6.1.2 Global Active Pharmaceutical Manufacturers for Drug
6.1.3 Approval Status of Drug
6.1.4 Patent and Exclusivity Details for Drug
6.1.5 Company Profile and Financials
7. Phase III Drugs for Erectile Dysfunction
7.1 Drug Name
7.1.1 Drug Description
7.1.2 United States Drug Master File (DMF)
8. Discontinued Drugs for Erectile Dysfunction
9. Appendix
10. Methodology
11. Consulting Services
12. Contact Us
13. Disclaimer


List of Tables

- Erectile Dysfunction Therapeutic Market, US, Marketed Drugs by Application Type, 2017
- Erectile Dysfunction Therapeutic Market, US, Marketed Drugs by Marketing Status, 2017
- Erectile Dysfunction Therapeutic Market, US, (Year), 2017
- Erectile Dysfunction Marketed Drugs, API Manufacturers by US DMF Status, 2017
- Erectile Dysfunction Marketed Drugs, US DMF Status Drug Specific (Number), 2017
- Erectile Dysfunction Drugs, API Manufacturers, Europe by Country, 2017
- Erectile Dysfunction Drugs, API Manufacturers, India by State, 2017
- Erectile Dysfunction Drugs, API Manufacturers, China by Province, 2017
- Erectile Dysfunction Drugs, API Manufacturers by Geography 2017
- Erectile Dysfunction Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2017
- Erectile Dysfunction Therapeutic Market, Global Sales-2018 (in million USD)
- API Manufacturers for Drug, 2017
- Phase III Drugs for Erectile Dysfunction, 2017
- Discontinued Drugs for Erectile Dysfunction, 2017


List of Figures

- Erectile Dysfunction Therapeutic Market, US, Marketed Drugs by Application Type (%), 2017
- Erectile Dysfunction Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2017
- Erectile Dysfunction Therapeutic Market, US, (Year), 2017
- Erectile Dysfunction Marketed Drugs, API Manufacturers by US DMF Status (%), 2017
- Erectile Dysfunction Marketed Drugs, US DMF Status Drug Specific (Number), 2017
- Erectile Dysfunction Drugs, API Manufacturers, Europe by Country, 2017
- Erectile Dysfunction Drugs, API Manufacturers, India by State, 2017
- Erectile Dysfunction Drugs, API Manufacturers, China by Province, 2017
- Erectile Dysfunction Drugs, API Manufacturers by Geography 2017
- Erectile Dysfunction Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2017
- Erectile Dysfunction Therapeutic Market, Global Sales 2018 (in million USD)
- Drug, Patent/Exclusivity Expiry (Year), 2017

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Global Erectile Dysfunction Drugs Market Research Report 2016

Global Erectile Dysfunction Drugs Market Research Report 2016

  • $ 2850
  • Industry report
  • December 2016
  • by 9Dimen Research

2016 Global Erectile Dysfunction Drugs Industry Report is a professional and in-depth research report on the world's major regional market conditions of the Erectile Dysfunction Drugs industry, focusing ...

Erectile Dysfunction  - Epidemiology Forecast To 2023

Erectile Dysfunction  - Epidemiology Forecast To 2023

  • $ 2750
  • Industry report
  • January 2017
  • by Delve Insight

DelveInsight “Erectile Dysfunction  - Epidemiology Forecast To 2023” provides an overview of the epidemiology trends of Erectile Dysfunction  in seven major markets (US, France, Germany, Italy, Spain, ...

Global Erectile Dysfunction Market 2016-2020

Global Erectile Dysfunction Market 2016-2020

  • $ 2500
  • Industry report
  • September 2016
  • by Infiniti Research Limited

About Erectile Dysfunction The loss of erection can be attributed to various factors such as high blood pressure, aging, diabetes mellitus, smoking, alcoholism, depression, nerve or spinal cord damage, ...


Download Unlimited Documents from Trusted Public Sources

Opioid and Dysfunction Drug Market in Canada

  • October 2016
    71 pages
  • Opioid  

    Dysfunction Dru...  

  • Canada  

View report >

Dysfunction Drug Market and Genitourinary System Disease Statistics in the UK

  • August 2016
    15 pages
  • Dysfunction Dru...  

    Genitourinary S...  

    Dermatological ...  

  • United Kingdom  

View report >

Dysfunction Drug Market in the UK and the US - Forecast

  • August 2016
    6 pages
  • Dysfunction Dru...  

    Diabetes  

  • United Kingdom  

    United States  

View report >

Therapy Market

6 hours ago

Related Market Segments :

Dysfunction Drug
Cloud Computing

ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.